# Go-CHOP as the Frontline Therapy for PTCL

> **NCT05963347** · PHASE2 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** Golidocitinib
- **DRUG:** CHOP Regimen

## Key facts

- **NCT ID:** NCT05963347
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-03
- **Primary completion:** 2025-07-30
- **Final completion:** 2026-07-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2023-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05963347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05963347, "Go-CHOP as the Frontline Therapy for PTCL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05963347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*